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Background and Methods: To define the value of septal ablation (PTSMA) as compared to surgical myectomy, we analyzed the long-term 
outcome of the first 347 consecutive patients (pts., mean age: 54±15 years) treated with PTSMA for symptomatic hypertrophic obstructive 
cardiomyopathy (HOCM) between 1996 and 2005. Data were acquired by outpatient examination in our own institution or by phone contact with 
the pts.’ local cardiologist. Pts. who could not be traced neither personally nor via their local physician or their health insurance company were 
considered “lost” to follow-up.
Results: During in-hospital stay following intervention, 4 pts. (1%) died. Mean CK rise was 534±258 U/l. A DDD-pacemaker (DDD-PM) had to be 
implanted in 26 pts. (7%) for PTSMA-induced AV conduction problems.
Follow-up was 99% complete (n=345). During follow-up (79±40 [range: 3-162] months), 33 pts. (10%) died, 17 of these (5%) from non-cardiac, and 
16 (5%) from cardiovascular causes. Overall survival was 93% at 5 years, and 90% at 10 years. A re-intervention for significant residual or recurrent 
outflow obstruction (LVOTO) was necessary in 27 pts. (8%; re-PTSMA: 18 pts.; myectomy: 9 pts). These cases included, at their last follow-up visit 
304 pts. (88%) were in functional class I or II.
There were 6 additional DDD-PM implantations (2%) and 17 (4%) ICD implantations (5 for secondary, 12 for primary prevention of sudden cardiac 
death) in our pt. cohort. The most frequent clinical problem was atrial fibrillation which occurred in 46 pts. (13%), and which was refractory to 
rhythm control attempts in 26 pts. (8%).
Conclusions: During long-term follow up following PTSMA, a persistent clinical improvement was observed. A second intervention (surgical or 
catheter-based) was needed in about 10%. Atrial fibrillation was a frequent problem. A total mortality rate of 33/347 (10%) or 1.5%/pt.-year, 
including all procedure-related deaths, compares favourably with the natural course of this pt. group with severe disease, and seems to be 
equivalent to post-myectomy data.
